Moreover, in glioblastoma, which is a highly vascularized type of cancer deemed ideal target for anti-VEGF therapy, it was shown that anti-VEGF therapy improves progression-free survival in newly diagnosed and recurrent glioblastoma, while it was recently suggested that continuing anti-VEGF treatment through multiple lines of therapy might prove beneficial to the patients (93). Here, VEGFA is linked to glioblastoma.